https://scholars.lib.ntu.edu.tw/handle/123456789/638440
標題: | Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial | 作者: | Brose, Marcia S Robinson, Bruce G Sherman, Steven I Jarzab, Barbara CHIA-CHI LIN Vaisman, Fernanda Hoff, Ana O Hitre, Erika Bowles, Daniel W Sen, Suvajit Oliver, Jennifer W Banerjee, Kamalika Keam, Bhumsuk Capdevila, Jaume |
關鍵字: | COSMIC-311; cabozantinib; differentiated thyroid cancer; phase 3; placebo; tyrosine kinase inhibitor | 公開日期: | 15-十二月-2022 | 卷: | 128 | 期: | 24 | 來源出版物: | Cancer | 摘要: | At an interim analysis (median follow-up, 6.2 months; n = 187), the phase 3 COSMIC-311 trial met the primary end point of progression-free survival (PFS): cabozantinib improved PFS versus a placebo (median, not reached vs. 1.9 months; p < .0001) in patients with previously treated radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). The results from an exploratory analysis using an extended datacut are presented. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638440 | ISSN: | 0008543X | DOI: | 10.1002/cncr.34493 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。